GlassScriptPhysician profile
Melissa D Parks
NPI 1114277324
$8,303.84
in general payments reported to CMS, 2019-2025
49 companies · $2,709 in 2025
The $2,709 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.64 · 2022: $356 · 2023: $1,922 · 2024: $3,279 · 2025: $2,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,900 · Education: $9.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,900.31 |
| Education | $9.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $920.76 | 2023-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $876.86 | 2021-2025 | |
| Mdd US Operations, LLC | $553.53 | 2023-2024 | Gocovri, Gocovri |
| Eisai INC. | $424.39 | 2023-2025 | |
| Celgene Corporation | $405.55 | 2022-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $387.26 | 2023-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Acadia Pharmaceuticals INC | $367.41 | 2023-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $326.77 | 2023-2025 | |
| Argenx US, INC. | $322.56 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $309.39 | 2021-2025 | |
| Pfizer INC. | $288.74 | 2023-2025 | |
| Biogen, INC. | $282.18 | 2022-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $261.78 | 2022-2025 | Amyvid, Emgality, Kisunla |
| Sk Life Science, INC. | $260.02 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $174.61 | 2022-2025 | Ingrezza, Ongentys |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $170.89 | 2023-2024 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $169.50 | 2023-2025 | Fycompa |
| Neurelis, INC. | $141.79 | 2023-2025 | Valtoco |
| Mallinckrodt Hospital Products INC. | $136.97 | 2023-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $116.85 | 2023-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $102.66 | 2022-2025 | Vyepti |
| Axsome Therapeutics, INC. | $102.63 | 2023-2025 | Symbravo, Sunosi |
| Vanda Pharmaceuticals INC. | $94.39 | 2024-2025 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $94.18 | 2023-2024 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $91.81 | 2023-2025 | Ultomiris |
| Aucta Pharmaceuticals, INC. | $85.13 | 2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $84.70 | 2024-2025 | Tascenso Odt, Bafiertam |
| Amgen INC. | $83.97 | 2021-2025 | Aimovig, Uplizna |
| Sumitomo Pharma America, INC. | $60.46 | 2023-2024 | Aptiom |
| Genentech USA, INC. | $59.56 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Biohaven Pharmaceutical Holding Company LTD. | $59.24 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $56.33 | 2024-2025 | Wainua |
| Microtransponder, INC. | $47.21 | 2025 | |
| Csl Behring | $42.46 | 2023-2024 | Hizentra |
| Sunovion Pharmaceuticals INC. | $40.26 | 2022 | |
| Impel Pharmaceuticals LLC | $39.55 | 2024-2025 | Trudhesa |
| Grifols USA, LLC | $32.97 | 2023-2024 | Gamunex-C |
| Cvrx, INC. | $31.34 | 2025 | Barostim Neo System |
| Acorda Therapeutics, INC | $24.52 | 2023 | Inbrija |
| Tg Therapeutics, INC. | $20.70 | 2024 | |
| Azurity Pharmaceuticals, INC. | $19.35 | 2024 | Horizant |
| Springworks Therapeutics, INC. | $18.78 | 2025 | Gomekli |
| Impel Pharmaceuticals INC. | $18.15 | 2023 | Trudhesa |
| Janssen Biotech, INC. | $18.03 | 2025 | |
| Cala Health, INC. | $17.25 | 2023 | Cala Trio |
| Upsher-Smith Laboratories LLC | $16.24 | 2022 | |
| Abbott Laboratories | $15.38 | 2024 | Infinity |
| Corium, LLC | $14.78 | 2022 | |
| C2n Diagnostics, LLC | $14.00 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.